Clinical Trial

Emapalumab Treatment For Anticipated Clinical Benefit In Sepsis Driven By The Interferon-Gamma Endotype (The EMBRACE Trial)

Study acronym: EMBRACE
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
EMBRACE is a double-blind, randomized, placebo-controlled, phase IIa study that will be conducted in multiple Intensive Care Units (ICUs) and departments of Internal Medicine across Greece. It aims to investigate if treatment with emapalumab, a monoclonal antibody which blocks IFNγ, may improve the outcome of patients with sepsis driven by the IDS (endotype of IFNγ-driven sepsis) endotype. EMBRACE also aims to identify the best dosing regimen of emapalumab for the management of IDS.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2024-11-15; most recent amendment 2025-11-18.
Status change: Recruiting → Active, Not Recruiting 2025-11-18
Status change: Not Yet Recruiting → Recruiting 2025-03-16
Trial Details
NCT Number NCT06694701
Lead Sponsor Hellenic Institute for the Study of Sepsis
Conditions Sepsis
Enrollment 75 participants
Start Date 2025-03-22
Primary Completion 2026-11 (estimated)
Study Completion 2026-11 (estimated)
Updated on ClinicalTrials.gov 2025-11-19